Drug Type Bispecific antibody |
Synonyms MDX-210/MAK cells, Osidem, IDM 1 + [3] |
Target |
Action antagonists |
Mechanism CD64 antagonists(High affinity immunoglobulin gamma Fc receptor I antagonists), HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Ovarian Cancer | Phase 3 | United States | - | - |
| Ovarian Cancer | Phase 3 | Australia | - | - |
| Ovarian Cancer | Phase 3 | Canada | - | - |
| Ovarian Cancer | Phase 3 | Europe | - | |
| Ovarian Cancer | Phase 3 | North America | - | |
| Ovarian Cancer | Phase 3 | - | - |






